Absence of cochleotoxicity measured by standard and high-frequency pure tone audiometry in a trial of once- versus three-times-daily tobramycin in cystic fibrosis patients

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 7, 2006, Pages 2293-2299

  Mulheran, Michael ^a   Hyman Taylor, Pauline ^a   Tan, Kelvin H V ^b,c,e   Lewis, Sarah ^b   Stableforth, David ^d   Knox, Alan ^b   Smyth, Alan ^b,c  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^d BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^e GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CEFTAZIDIME; TOBRAMYCIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; AUDITORY THRESHOLD; CHILD; CLINICAL TRIAL; COCHLEOTOXICITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE EXACERBATION; DOSE RESPONSE; FOLLOW UP; HEARING; HUMAN; MAJOR CLINICAL STUDY; OTOTOXICITY; PRIORITY JOURNAL; PURE TONE AUDIOMETRY; RANDOMIZED CONTROLLED TRIAL; STANDARD;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AUDIOMETRY, PURE-TONE; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; DRUG ADMINISTRATION SCHEDULE; HEARING LOSS; HUMANS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TOBRAMYCIN; TREATMENT OUTCOME;

EID: 33745602275     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00995-05     Document Type: Article

References (28)

1. Anonymous. 1981. Recommended procedures for pure tone audiometry using a manually operated instrument. Br. J. Audiol. 15:213-216.
2. Anonymous. 1985. Recommended procedures for pure tone hone conduction audiometry without masking using a manually operated instrument. Br. J. Audiol. 19:281-282.
3. Anonymous. 1986. Recommendations for masking in pure tone threshold audiometry. Br. J. Audiol. 20:307-314.
4. Anonymous. 1992. Recommended procedure for tympanometry. Br. J. Audiol. 26:255-257.
5. Aran, J. M. 1995. Current perspectives on inner ear toxidty. Otolaryngol-Head Neck Surg. 112:133-144.
6. Arslan, E., E. Orzan, and R. Santarelli. 1999. Global problem of drug-induced hearing loss. Ann. N. Y. Acad. Sci. 884:1-14.
7. Barza, M., J. P. A. Ioannidis, J. C. Cappelleri, and J. Lau. 1996. Single or multiple daily doses of aminoglycosides: a meta-analysis. Br. Med. J. 312:338-345.
8. Cone, L. A. 1982. A survey of prospective controlled clinical trials of gentamicin, tobramycin amikacin and netilmicin. Clin. Ther. 5:155-162.
9. Department of Health (United Kingdom). 1994. Health building note 12; supplement ENT, audiology clinics and hearing aid centres. NHS Estates, Leeds, United Kingdom.
10. Flottorp, G. 1995. Improving audiometric thresholds by changing headphone position at the ear. Audiology 34:221-231.
11. Frank, T. 1990. High frequency hearing thresholds in young adults using a commercially available audiometer. Ear Hearing 11:450-454.
12. Govaerts, P. J., J. Claes, P. H. Van De Heyning, P. G. Jorens, G. Marquet, and M. E. De Broe. 1990. Aminoglycoside induced ototoxicity. Toxicol. Lett. 52:227-251.
13. Jensen, T., S. S. Pedersen, S. Garne, C. Heilmann, N. Hoiby, and C. Koch. 1987. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J. Antimicrob. Chemother. 19:831-838.
14. Kahlmeter, G., and J. I. Dahlager. 1982. Aminoglycoside ototoxicity-a review of clinical studies published between 1975 and 1982. Antimicrob. Chemother. 13(Suppl. A):9-22.
15. Konstan, M. W., P. J. Byard, C. L. Hoppel, and P. B. Davis. 1995. Effect of high-dose ibuprofen in patients with cystic fibrosis. N. Engl. J. Med. 332:848-854.
16. Lutman, M. E., and A. C. Davis. 1994. The distribution of hearing thresholds in the general population aged 18-30 years. Audiology 33:327-350.
17. Morizono, T. 1990. Toxicity of ototopical drugs: animal modeling. Ann. Otorhinolaryngol. 99:42-45.
18. Mulheran, M., C. Degg, D. Morgan, and D. E. Stableforth. 2001. The occurrence and risk of cochleotoxicity in cystic fibrosis patients receiving repeated high-dose aminoglycoside therapy. Antimicrob. Agents Chemother. 45:2502-2509.
19. Ngui-Yen, J. H., P. W. Doyle, and J. A. Smith. 1984. Comparative analysis of two rapid, automated methods for determining aminoglycoside levels. J. Clin. Microbiol. 20:962-965.
20. Pedersen, S., T. Jensen, D. Osterhammel, and P. Osterhammel. 1987. Cumulative and acute toxicity of repealed high dose tobramycin in cystic fibrosis. Antimicrob. Agents Chemother. 31:594-599.
21. Prins, J. M., and P. Speelman. 1998. Once-daily aminoglycosides: practical guidelines. Neth. J. Med. 52:1-9.
22. Robinson, D. W. 1988. Threshold of hearing as a function of age and sex for the typical unscreened population. Br. J. Audiol. 22:5-20.
23. Robinson, D. W. 1991. Long term repeatability of the pure tone hearing threshold and its relationship to noise exposure. Br. J. Audiol. 25:219-235.
24. Smyth, A., K. H-V. Tan, and H. Bunn. 2000. Once daily versus multiple daily dosing with intravenous aminoglycosides for cystic fibrosis. Cochrane Database Syst. Rev. 4:CD002009.
25. Smyth, A., K. Tan, P. Hyman-Taylor, M. Mulheran, S. Lewis, D. Stableforth, and A. Knox. 2005. Once versus three times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis-the TOPIC study: a randomised controlled trial. Lancet 365:573-578.
26. Tan, K. H.-V., M. Mulheran, A. J. Knox, and A. R. Smyth. 2003. Aminoglycoside prescribing and surveillance in cystic fibrosis. Am. J. Respir. Crit. Care Med. 167:819-823.
27. Touw, D. J., R. W. Brimicombe, M. E. Hodson, H. G. Heijerman, and W. Bakker. 1995. Inhalation of antibiotics in cystic fibrosis. Eur. Respir. J. 8:1594-1604.
28. Touw, D. J. 1998. Clinical pharmacokinetics of antimicrobial drugs in cystic fibrosis. Pharm. World Sci. 20:149-160.